Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20157713 | 0.92 | BRD4 (0.33) | BRD4 | |
| SCHEMBL21362105 | 0.89 | BRD4 (0.32) | BRD4LMNATP53MAPTHTT | |
| SCHEMBL21354474 | 0.88 | BRD4 (0.36) | BRD4MAPT | |
| SCHEMBL21351838 | 0.88 | BRD4 (0.36) | BRD4MAPT | |
| SCHEMBL21362108 | 0.88 | BRD4 (0.36) | BRD4MAPT | |
| SCHEMBL21351835 | 0.88 | BRD4 (0.36) | BRD4MAPT | |
| SCHEMBL21362079 | 0.87 | BRD4 (0.37) | BRD4LMNATP53MAPTHTT | |
| SCHEMBL21352243 | 0.87 | BRD4 (0.32) | BRD4LMNATP53MAPTHTT | |
| SCHEMBL21362174 | 0.86 | BRD4 (0.33) | BRD4LMNATP53MAPTHTT | |
| SCHEMBL21362128 | 0.84 | BRD4 (0.36) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284192-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284192-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | MYC, BRD1, BRD3 | BRD4 7/4885LMNA 2333/4885TP53 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.